Skip to main content

Branded

  • FDA approves Orexo’s low-dose Zubsolv
    SILVER SPRING, Md. — The Food and Drug Administration has approved Orexo’s Zubsolv (buprenorphine 0.7 mg/naloxone 0.18 mg) sublingual tablets, the company announced Thursday. The drug is indicated to treat patients with opioid dependence. 
     
    With this approval, Orexo now has FDA approval for six dosage strength tablets: 11.4 mg buprenorphine/2.9 mg naloxone, 8.6 mg/2.1 mg, 5.7 mg/1.5 mg, 2.9 mg/0.71 mg, 1.4 mg/0.36 mg and 0.7 mg/0.18 mg. 
     

  • Lupin, MonoSol Rx ink licensing agreement for pediatric products
    WARREN, New Jersey, BALTIMORE and MUMBAI — Lupin on Tuesday announced a new strategic licensing agreement with specialty pharmaceutical company MonoSol Rx. Under the agreement, Lupin would develop multiple pediatric products using Monosol Rx’s PharmFilm drug delivery technology. 
     

  • Health Canada approves Adapt Pharma’s Narcan Nasal Spray
    DUBLIN, Ireland — Health Canada on Tuesday approved naloxone hydrochloride nasal spray, a nasal delivery method for the opioid overdose medication, which Adapt Pharma said it would market as Narcan Nasal Spray. 
     

  • Jean Coutu Group launches flu shot awareness campaign

    VARENNES, Quebec - The Jean Coutu Group on Tuesday launched a flu shot awareness campaign under the theme "Protect Your Health and That of Your Loved Ones." The campaign aims to support the public health effort for flu prevention by making the flu shot available in more than 300 stores in the Jean Coutu network throughout Quebec, in Ontario and New Brunswick.

  • Eisai, Arena announce availability of Belviq XR
    WOODCLIFF LAKE, N.J. — Eisai and Arena Pharmaceuticals have announced the availability of Belviq XR (lorcaserin HCl) extended-release tablets. The new formulation offers a once-daily dosing option that the company says may help some patients achieve and maintain weight loss. 
     

  • Prime Therapeutics finds increase in long-acting opioid claims
    ST. PAUL, Minn. — Pharmacy benefit manager Prime Therapeutics recently analyzed pharmacy claims for short- and long-acting opioids, finding a decrease in short-acting opioid claims and an increase in long-acting opioid claims. The review of 15 million commercially insured members found an overall 3.9% decrease in opioid claims from 2014 to 2015. 
     

  • CDC recommends getting flu shot before end of October

    WASHINGTON - The National Foundation for Infectious Diseases joined the Centers for Disease Control and Prevention Thursday morning to advocate everyone over the age of six months get vaccinated against influenza this year, preferably by the end of October - "A vaccination deferred is a vaccination forgotten," Tom Frieden, director CDC, said.

  • FDA approves Janssen’s Stelara to treat Crohn’s disease
    SILVER SPRING, Md. — Janssen Biotech announced Monday that the Food and Drug Administration had approved its Stelara (ustekinumab) to treat moderately to severely active Crohn’s disease.  
     
    It is now indicated for adults with Crohn’s disease who have failed or were intolerant to corticosteroid or immunomodulator treatments, but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant of one or more TNF blocker treatment. 
     
X
This ad will auto-close in 10 seconds